{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:59:57Z","timestamp":1789275597861,"version":"build-2803163510"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues, toxicities associated with the infusion of the product, and relapses of the tumor. As a result, novel approaches are appearing aiming to solve and\/or mitigate the harmful effects of CAR-T therapies. These include strategies based on the use of ligands as binding moieties or ligand-based CAR-T cells. Several proposals are currently under development, with some undergoing clinical trials to assess their potential benefits. In addition to these, therapies such as chimeric autoantibody receptor (CAAR), B-cell receptor antigen for reverse targeting (BAR), and even chimeric human leukocyte antigen (HLA) antibody receptor (CHAR) have emerged, benefiting from the advantages of antigenic ligands as antibody-binding motifs. This review focuses on the potential role that ligands can play in current and future antitumor treatments and in other types of diseases, such as autoimmune diseases or problems associated with transplantation.<\/jats:p>","DOI":"10.3389\/fimmu.2022.932559","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:31:29Z","timestamp":1662967889000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments"],"prefix":"10.3389","volume":"13","author":[{"given":"Alejandro","family":"Ram\u00edrez-Chac\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Betriu-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Bartol\u00f3-Ibars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azucena","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"4379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2591","article-title":"CAR T-cell therapy: Full speed ahead","author":"Sermer","year":"2019","journal-title":"Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.12.047","article-title":"Current challenges and emerging opportunities of CAR-T cell therapies","volume":"319","author":"Abreu","year":"2020","journal-title":"J Control Release"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2020-001290","article-title":"CAR-T treatment for hematological malignancies","volume":"68","author":"Atrash","year":"2020","journal-title":"J Investig Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable remissions in children with Relapsed\/Refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019)","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory Large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00482","article-title":"Point-Of-Care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: Experience from an academic phase I clinical trial","volume":"11","author":"Catell\u00e0","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA Approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O'Learly","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval summary: Axicabtagene ciloleucel for relapsed or refractory Large b-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B14","unstructured":"FDA"},{"key":"B15","unstructured":"FDA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: A multicenter trial of ARI-0001 cell therapy in patients with CD19 + Relapsed\/Refractory malignancies","volume":"29","author":"Ort\u00edz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"key":"B17","unstructured":"FDA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136307","article-title":"CARTITUDE-1: Phase 1b\/2 study of ciltacabtagene autoleucel, a b-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in Relapsed\/Refractory multiple myeloma","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00069","article-title":"Next generation CAR T cells for the immunotherapy of high-grade glioma","volume":"69","author":"Petersen","year":"2019","journal-title":"Front Oncol"},{"key":"B22","unstructured":""},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144787","article-title":"Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors","volume":"10","author":"Karlsson","year":"2015","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"112692","DOI":"10.1016\/j.jim.2019.112692","article-title":"A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel","volume":"476","author":"Potthoff","year":"2020","journal-title":"J Immunol Methods"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/med.21818","article-title":"The antigen-binding moiety in the driver\u2019s seat of CARs","volume":"42","author":"Hanssens","year":"2021","journal-title":"Med Res Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000653","article-title":"New targets and technologies for CAR-T cells","volume":"32","author":"Fabian","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2778","article-title":"Genetically modified T cells targeting interleukin-11 receptor \u03b1-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases","volume":"72","author":"Huang","year":"2012","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.009","article-title":"Adnectin-based design of chimeric antigen receptor for T cell engineering","volume":"25","author":"Han","year":"2017","journal-title":"Mol Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134395","article-title":"Mutated GM-CSF-Based CAR T-cells targeting CD116\/CD131 complexes exhibit enhanced anti-tumor effects against acute myeloid leukemia","volume":"136","author":"Saito","year":"2020","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.03.001","article-title":"Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma","volume":"20","author":"Kubo","year":"2021","journal-title":"Mol Ther - Oncolytics"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric April-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00283-5","article-title":"Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells","volume":"29","author":"Zoine","year":"2021","journal-title":"Gene Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-021-00536-x","article-title":"Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells","volume":"11","author":"Chen","year":"2021","journal-title":"Blood Cancer J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"107419","DOI":"10.1016\/j.pharmthera.2019.107419","article-title":"Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions","volume":"205","author":"Bagley","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-5027-4","article-title":"Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3897","article-title":"Interleukin-11: Review of molecular, cell biology, and clinical use","volume":"89","author":"Du","year":"1997","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.17","article-title":"IL-11 signaling as a therapeutic target for cancer","volume":"7","author":"Putoczki","year":"2015","journal-title":"Immunotherapy"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000298","article-title":"Future directions in the treatment of osteosarcoma","volume":"28","author":"Bishop","year":"2016","journal-title":"Curr Opin Pediatr"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4845","article-title":"The interleukin-11 receptor \u03b1 as a candidate ligand-directed target in osteosarcoma: Consistent data from cell lines, orthotopic models, and human tumor samples","volume":"69","author":"Lewis","year":"2009","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2675","article-title":"Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer","volume":"64","author":"Zurita","year":"2004","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11912-015-0459-8","article-title":"Adnectin-targeted inhibitors: rationale and results","volume":"17","author":"Sachdev","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0386-6","article-title":"In vitro-engineered non-antibody protein therapeutics","volume":"9","author":"Simeon","year":"2018","journal-title":"Protein Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7219-7_1","article-title":"ErbB receptors and cancer","volume":"1652","author":"Wang","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.14168","article-title":"A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor","volume":"3","author":"Emanuel","year":"2011","journal-title":"mAbs"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183161","article-title":"EphB4\/EphrinB2 therapeutics in rhabdomyosarcoma","volume":"12","author":"Randolph","year":"2017","journal-title":"PLoS One"},{"key":"B53","article-title":"Up-regulation of EphB and ephrin-b expression in rhabdomyosarcoma","volume":"28","author":"Berardi","year":"2008","journal-title":"Anticancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1073\/pnas.0401381101","article-title":"Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth","volume":"101","author":"Noren","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.03.001","article-title":"Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma","volume":"20","author":"Kubo","year":"2021","journal-title":"Mol Ther - Oncolytics"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.11.017","article-title":"Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma","volume":"365","author":"Kikuchi","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the united kingdom medical research council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07491.x","article-title":"Interleukin (IL)-3\/granulocyte macrophage-colony stimulating factor\/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor","volume":"144","author":"Riccioni","year":"2009","journal-title":"Br J Haematol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/leu.2017.147","article-title":"Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: From basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol Rev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol Rev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.05.030","article-title":"GM-CSF: An immune modulatory cytokine that can suppress autoimmunity","volume":"75","author":"Bhattacharya","year":"2015","journal-title":"Cytokine"},{"key":"B63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-016-0256-3","article-title":"Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia","volume":"9","author":"Nakazawa","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05129.x","article-title":"Residue 21 of human granulocyte-macrophage colony-stimulating factor is critical for biological activity and for high but not low affinity binding -","volume":"11","author":"L\u00f3pez","year":"1992","journal-title":"EMBO J"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278218","article-title":"T Cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"B69","article-title":"Brain tumor-specific immune cells (IL13Ralpha2-CAR T cells) for the treatment of leptomeningeal glioblastoma, ependymoma, or medulloblastoma","volume-title":"ClinicalTrials.gov","author":"Feldman","year":"2022"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.014944","article-title":"Current challenges and opportunities in treating glioblastoma","volume":"70","author":"Shergalis","year":"2018","journal-title":"Pharmacol Rev"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103695","article-title":"Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients","volume":"12","author":"Gao","year":"2020","journal-title":"Aging"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077769","article-title":"Glioma IL13R\u03b12 is associated with mesenchymal signature gene expression and poor patient prognosis","volume":"8","author":"Brown","year":"2013","journal-title":"PloS One"},{"key":"B73","article-title":"Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas","volume":"5","author":"Debinski","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou045","article-title":"Significance of interleukin-13 receptor alpha 2\u2013targeted glioblastoma therapy","volume":"16","author":"Thaci","year":"2014","journal-title":"Neuro Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-1064","article-title":"Silencing IL-13R\u03b12 promotes glioblastoma cell death via via endogenous signaling","volume":"10","author":"Hsi","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1333","article-title":"IL-13 receptors and signaling pathways: an evolving web","volume":"111","author":"Hershey","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0454","article-title":"Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells","volume":"64","author":"Kahlon","year":"2004","journal-title":"Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1669","article-title":"Stem-like tumor-initiating cells isolated from IL13R\u03b12 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells","volume":"18","author":"Brown","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B79","article-title":"Cellular adoptive immunotherapy using genetically modified T-lymphocytes in treating patients with recurrent or refractory high-grade malignant glioma","volume-title":"ClinicalTrials.gov","author":"Forman","year":"2011"},{"key":"B80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol Ther"},{"key":"B81","article-title":"Genetically modified T-cells in treating patients with recurrent or refractory malignant glioma","volume-title":"ClinicalTrials.gov","author":"Brown","year":"2014"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1016140108","article-title":"Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase","volume":"108","author":"Garrett","year":"2011","journal-title":"PNAS"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00493","article-title":"Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells","volume":"18","author":"Davies","year":"2012","journal-title":"Mol Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary \u2018T4 immunotherapy\u2019 of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301119","article-title":"Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin","volume":"191","author":"Parente-Pereira","year":"2013","journal-title":"J Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M305603200","article-title":"Structural analysis of an epidermal growth factor\/transforming growth factor-\u03b1 chimera with unique ErbB binding specificity","volume":"278","author":"Wingens","year":"2003","journal-title":"J Biol Chem"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1021\/bi012016n","article-title":"Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2\/ErbB-3 heterodimers","volume":"41","author":"Stortelers","year":"2002","journal-title":"Biochemistry"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.127951","article-title":"Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4","volume":"285","author":"Wilkie","year":"2010","journal-title":"J Biol Chem"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301523","article-title":"Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity","volume":"191","author":"Van Der Stegen","year":"2013","journal-title":"J Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2013.144","article-title":"Design of a phase i clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer","volume":"24","author":"Van Schalkwyk","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2727-2_21","article-title":"Clinical evaluation of ErbB-targeted CAR T-cells, following intracavity delivery in patients with ErbB-expressing solid tumors","volume":"1317","author":"Papa","year":"2015","journal-title":"Methods Mol Biol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061473","article-title":"BCMA-targeting therapy: Driving a new era of immunotherapy in multiple myeloma","volume":"12","author":"Cho","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T Cells expressing an anti-b-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312316200","article-title":"Engineering an APRIL-specific b cell maturation antigen *","volume":"279","author":"Patel","year":"2004","journal-title":"J Biol Chem"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M411714200","article-title":"Structures of APRIL-receptor complexes: Like bcma, taci employs only a single cysteine-rich domain for high affinity ligand binding","volume":"280","author":"Hymowitz","year":"2005","journal-title":"J Biol Chem"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115348","article-title":"BAR-bodies: B-cell receptor antigens as the targeting moiety of antibodies in substitution for the variable region of heavy and light chains","volume":"132","author":"Bewarder","year":"2018","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.06.001","article-title":"Antibody therapeutics and immunoregulation in cancer and autoimmune disease","volume":"64","author":"Yasunaga","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"E620","DOI":"10.1097\/HS9.0000000000000620","article-title":"The b-cell receptor autoantigen LRPAP1 can replace variable antibody regions to target mantle cell lymphoma cells","volume":"5","author":"Bewarder","year":"2021","journal-title":"HemaSphere"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0182-1","article-title":"LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting","author":"Thurner","year":"2018","journal-title":"Leuk"},{"key":"B108","doi-asserted-by":"publisher","first-page":"849835","DOI":"10.1155\/2013\/849835","article-title":"Incidence and clinical significance of de novode novo donor specific antibodies after kidney transplantation","volume":"2013","author":"Lionaki","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.81","article-title":"The impact of donor-specific anti-HLA antibodies on late kidney allograft failure","volume":"8","author":"Loupy","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.03.003","article-title":"Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies","volume":"31","author":"Murad","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/10.4.435","article-title":"Disrupting the hydrophobic patches at the antibody variable\/constant domain interface: improved in vivoin vivo folding and physical characterization of an engineered scFv fragment","volume":"10","author":"Nieba","year":"1997","journal-title":"Protein Eng Des Sel"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"Chen YY. T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant b cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: Principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.12.7647","article-title":"T Cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity","volume":"173","author":"Chmielewski","year":"2004","journal-title":"J Immunol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2022.1078003","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.932559\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T13:50:29Z","timestamp":1669038629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.932559\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":114,"alternative-id":["10.3389\/fimmu.2022.932559"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.932559","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2022.1078003","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"932559"}}